CDKN2A and astrocytoma (excluding glioblastoma): We refine the molecular criteria for IDH1/2-mutant astrocytoma by augmenting histologic grade with hemizygous CDKN2A/B deletion and focal gene amplifications to establish three prognostically distinct tiers.4,11,12